{"pmid":32461492,"title":"COVID-19: Ophthalmic prophylactic and therapeutic measures.","text":["COVID-19: Ophthalmic prophylactic and therapeutic measures.","Indian J Ophthalmol","Waikar, Shrikant","Oli, Avadhesh","32461492"],"journal":"Indian J Ophthalmol","authors":["Waikar, Shrikant","Oli, Avadhesh"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461492","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.4103/ijo.IJO_883_20","topics":["Treatment","Prevention"],"weight":1,"_version_":1668079521313587200,"score":9.490897,"similar":[{"pmid":32294495,"pmcid":"PMC7152897","title":"Chloroquine as a prophylactic agent against COVID-19?","text":["Chloroquine as a prophylactic agent against COVID-19?","Int J Antimicrob Agents","Gendrot, Mathieu","Javelle, Emilie","Le Dault, Erwan","Clerc, Axelle","Savini, Helene","Pradines, Bruno","32294495"],"journal":"Int J Antimicrob Agents","authors":["Gendrot, Mathieu","Javelle, Emilie","Le Dault, Erwan","Clerc, Axelle","Savini, Helene","Pradines, Bruno"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294495","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.ijantimicag.2020.105980","e_drugs":["Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138494442930176,"score":46.151558},{"pmid":32302280,"title":"Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.","text":["Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.","As of March 30(th), 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.(2) We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective.","West J Emerg Med","Brown, Cortlyn","Noble, Jeanne","Coralic, Zlatan","32302280"],"abstract":["As of March 30(th), 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.(2) We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective."],"journal":"West J Emerg Med","authors":["Brown, Cortlyn","Noble, Jeanne","Coralic, Zlatan"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302280","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.5811/westjem.2020.3.47328","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Treatment"],"weight":1,"_version_":1666138494899060736,"score":42.343178},{"pmid":32054787,"pmcid":"PMC7104368","title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.","text":["Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.","The continued emergence of Middle East Respiratory Syndrome (MERS) cases with a high case fatality rate stresses the need for the availability of effective antiviral treatments. Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro, and showed efficacy against Severe Acute Respiratory Syndrome (SARS)-CoV in a mouse model. Here, we tested the efficacy of prophylactic and therapeutic remdesivir treatment in a nonhuman primate model of MERS-CoV infection, the rhesus macaque. Prophylactic remdesivir treatment initiated 24 h prior to inoculation completely prevented MERS-CoV-induced clinical disease, strongly inhibited MERS-CoV replication in respiratory tissues, and prevented the formation of lung lesions. Therapeutic remdesivir treatment initiated 12 h postinoculation also provided a clear clinical benefit, with a reduction in clinical signs, reduced virus replication in the lungs, and decreased presence and severity of lung lesions. The data presented here support testing of the efficacy of remdesivir treatment in the context of a MERS clinical trial. It may also be considered for a wider range of coronaviruses, including the currently emerging novel coronavirus 2019-nCoV.","Proc Natl Acad Sci U S A","de Wit, Emmie","Feldmann, Friederike","Cronin, Jacqueline","Jordan, Robert","Okumura, Atsushi","Thomas, Tina","Scott, Dana","Cihlar, Tomas","Feldmann, Heinz","32054787"],"abstract":["The continued emergence of Middle East Respiratory Syndrome (MERS) cases with a high case fatality rate stresses the need for the availability of effective antiviral treatments. Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro, and showed efficacy against Severe Acute Respiratory Syndrome (SARS)-CoV in a mouse model. Here, we tested the efficacy of prophylactic and therapeutic remdesivir treatment in a nonhuman primate model of MERS-CoV infection, the rhesus macaque. Prophylactic remdesivir treatment initiated 24 h prior to inoculation completely prevented MERS-CoV-induced clinical disease, strongly inhibited MERS-CoV replication in respiratory tissues, and prevented the formation of lung lesions. Therapeutic remdesivir treatment initiated 12 h postinoculation also provided a clear clinical benefit, with a reduction in clinical signs, reduced virus replication in the lungs, and decreased presence and severity of lung lesions. The data presented here support testing of the efficacy of remdesivir treatment in the context of a MERS clinical trial. It may also be considered for a wider range of coronaviruses, including the currently emerging novel coronavirus 2019-nCoV."],"journal":"Proc Natl Acad Sci U S A","authors":["de Wit, Emmie","Feldmann, Friederike","Cronin, Jacqueline","Jordan, Robert","Okumura, Atsushi","Thomas, Tina","Scott, Dana","Cihlar, Tomas","Feldmann, Heinz"],"date":"2020-02-15T11:00:00Z","year":2020,"_id":"32054787","source":"PubMed","week":"20207|Feb 10 - Feb 16","doi":"10.1073/pnas.1922083117","keywords":["mers-cov","animal model","antiviral","remdesivir","therapy"],"e_drugs":["remdesivir"],"topics":["Treatment"],"weight":1,"_version_":1666138492992749570,"score":41.373405},{"pmid":32402522,"title":"Prophylactic anticoagulant therapy for reducing the risk of stroke and other thrombotic events in COVID-19 patients.","text":["Prophylactic anticoagulant therapy for reducing the risk of stroke and other thrombotic events in COVID-19 patients.","J Formos Med Assoc","Aghamohammadi, Mehdi","Alizargar, Javad","Hsieh, Nan-Chen","Wu, Shu-Fang Vivienne","32402522"],"journal":"J Formos Med Assoc","authors":["Aghamohammadi, Mehdi","Alizargar, Javad","Hsieh, Nan-Chen","Wu, Shu-Fang Vivienne"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32402522","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jfma.2020.05.005","locations":["Prophylactic"],"topics":["Treatment"],"weight":1,"_version_":1666714494830641152,"score":40.78922}]}